Solid tumours

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Solid tumours

New DDW Highlights podcast: 26 February 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a breakthrough for advanced therapies, this week saw the FDA approve the first… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Solid tumours

This week in drug discovery (19-23 February) 

News round-up for 19-23 February by DDW Digital Content Editor Diana Spencer. In a breakthrough for advanced therapies, this week saw the FDA approve the first ever cell therapy for solid tumour cancers, but there were other significant developments in the cell and gene therapy space. The… Read More

#News

T cells attacking cancer
#Cell and gene therapy #Cell therapy #FDA #Iovance #Melanoma #Oncology #Solid tumours

FDA approves first T cell therapy in solid tumours

The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. It is approved for use in adults that have previously been treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a… Read More

#News #Regulatory #Trending News

#Bispecific Antibodies #Cancer treatment #Checkpoint inhibitor therapies #Clinical trials #Solid tumours

Phase I trial for first-in-class bispecific antibody for cancer

Onward Therapeutics has announced the Phase I clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress.  The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoural activity of OT-A201.   The study is a European multicentre and… Read More

#Cancer Research #News

Cancer cells
#Cancer research #Immunotherapy #Nimbus #Oncology #Phase I trial #Solid tumours

HPK1 inhibitor demonstrates clinical benefit in solid tumours

Initial data from an ongoing Phase I/II study of HPK1 inhibitor NDI-101150 show clinical benefit in three patients with solid tumours, including one complete response in a patient with renal cell carcinoma. Two patients with pancreatic cancer and renal cell carcinoma, respectively, exhibited prolonged (> six… Read More

#Cancer Research #News

Cancer research
#Cancer research #Kura Oncology #Oncology #Phase I trial #Solid tumours

Farnesyl transferase inhibitor for solid tumours enters trials

Kura Oncology’s FIT-001 Phase I dose-escalation trial of KO-2806, a farnesyl transferase inhibitor (FTI) for the treatment of advanced solid tumours, has commenced with the dosing of the first patient. FIT-001 is a first-in-human, multicentre, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary… Read More

#Cancer Research #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Cancer research #Iksuda Therapeutics #Oncology #Phase I trial #Solid tumours

First patient dosed with antibody drug conjugate for HER2+ tumours

Iksuda Therapeutics has dosed the first patient in a Phase I trial of antibody drug conjugate (ADC) IKS014 in patients with advanced solid tumours that express HER2. This follows positive data from Phase I clinical trials through Fosun Pharma, which is now progressing FS-1502 (IKS014) through… Read More

#Cancer Research #News

CAR-T therapy
#Cancer research #CAR-T #CARsgen Therapeutics #China #Oncology #Solid tumours

CAR T therapy successfully treats solid tumours in China

CARsgen has published evidence of over seven years of disease-free survival in advanced hepatocellular carcinoma (HCC) following treatment with its CAR-GPC3 T cell therapy. Hepatocellular carcinoma is one of the most common malignant tumours, with approximately 780,000 annual incidence cases globally. Recurrence and metastasis are common. Read More

#Cancer Research #Editor's Choice #News

IgG1 monoclonal antibody
#Artificial intelligence (AI) #Aulos Bioscience #Monoclonal antibodies #Oncology #Phase I trial #Solid tumours

Data supports IgG1 monoclonal antibody for solid tumours

Aulos Bioscience has revealed new safety and efficacy data from the Phase I dose escalation portion of its Phase I/II clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumour cancers. The data will be presented at the Society for Immunotherapy of… Read More

#Cancer Research #News

CAR-T therapy
#Cancer research #CAR-T #Leucid Bio #MHRA #Oncology #Solid tumours

CAR-T therapy targets over 80% of human tumours

Leucid Bio has been granted clinical trial authorisation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours. The open-label, single patient cohort ascending… Read More

#Cancer Research #Editor's Choice #News

#Cancer research #CAR-T #Cell and gene therapy #Collaboration #Oncology #Solid tumours

New DDW Highlights podcast now live

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news headlines this week reflect the level of interest in cell & gene… Read More

#News

Tumour microenvironment
#Cancer research #Cancer Research UK #Immunotherapy #Oncology #Phase I trial #Solid tumours #Sosei Heptares

Immunotherapy for solid tumours progresses to human trials

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. Sosei Group and Cancer Research UK announced that the first patient has been dosed in a Phase I/IIa clinical trial evaluating… Read More

#Cancer Research #News

#Cancer research #CAR-T #Cell and gene therapy #Collaboration #Oncology #Solid tumours

This week in drug discovery (7-11 August)  

News round-up for by DDW Digital Content Editor Diana Spencer. The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. Traditionally successful… Read More

#News

CAR-T therapy
#Cancer research #CAR-T #Collaboration #GenScript Biotech #Solid tumours #T-MAXIMUM Biotech

Collaborators agree deal to develop CAR-T therapy for solid tumours

GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM’s CAR-T cell therapy using GenScript’s CRISPR nucleic acid reagents. GenScript will provide various CRISPR reagents to support the development of the universal CAR-T products from discovery to commercialisation. T-MAXIMUM Biotech hopes… Read More

#Business & Investment #News

CAR-T cells attack cancer cells
#Astellas Pharma #Cancer research #CAR-T #Cell therapy #Investment #Poseida Therapeutics #Solid tumours

Astellas invests in CAR-T cell therapy for solid tumours

Astellas Pharma will invest $50 million into Poseida Therapeutics to secure the rights to the company’s cancer CAR-T cell therapy for solid tumours, which is currently in Phase I trials. The total $50 million will include $25 million to acquire 8,333,333 shares of common stock of… Read More

#Business & Investment #News

T cells
#Cancer research #Icahn School of Medicine #Immunotherapy #Melanoma #mRNA #Oncology #Solid tumours

RNA strategy activates dendritic cells and eradicates melanoma tumours

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The findings, which suggest that the approach has the potential to be effective against tumours… Read More

#Cancer Research #Editor's Choice #News